S2Medical AB Cash Flow Conversion Efficiency
S2Medical AB cash flow conversion efficiency. Based on the latest financial reports, S2Medical AB (S2M) has a cash flow conversion efficiency ratio of 0.017x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr169.00K ≈ $18.19K USD) by net assets (Skr10.06 Million ≈ $1.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of S2Medical AB (2016–2025)
Cash flow conversion efficiency of S2Medical AB from 2016 to 2025. This chart illustrates how S2Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View S2Medical AB share price for real-time trading data and today's change.
S2Medical AB Cash Flow Conversion Ratio Explained
S2Medical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
S2Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of S2Medical AB ranked by their cash flow conversion efficiency. Also see market value of S2Medical AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crystal Amber Fund Limited
LSE:CRS
|
-0.003x |
|
T-Bull S.A
WAR:TBL
|
0.251x |
|
Queste Communications Ltd
AU:QUE
|
-0.021x |
|
Venus Concept Inc
NASDAQ:VERO
|
-1.560x |
|
Manz AG
F:M5Z
|
-0.114x |
|
Oxford Metrics plc
LSE:OMG
|
0.026x |
|
Redan S.A.
WAR:RDN
|
-0.002x |
|
Groupimo SA
PA:ALIMO
|
0.025x |
Annual Cash Flow Conversion Efficiency for S2Medical AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of S2Medical AB from 2016 to 2025. Review S2Medical AB (S2M) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr9.87 Million ≈ $1.06 Million |
Skr675.00K ≈ $72.64K |
0.068x | -83.96% |
| 2024-12-31 | Skr11.80 Million ≈ $1.27 Million |
Skr5.03 Million ≈ $541.40K |
0.426x | +104.28% |
| 2023-12-31 | Skr1.66 Million ≈ $178.42K |
Skr-16.52 Million ≈ $-1.78 Million |
-9.964x | -150.39% |
| 2022-12-31 | Skr7.07 Million ≈ $760.76K |
Skr-28.13 Million ≈ $-3.03 Million |
-3.979x | -197.08% |
| 2021-12-31 | Skr14.68 Million ≈ $1.58 Million |
Skr-19.67 Million ≈ $-2.12 Million |
-1.339x | -244.25% |
| 2020-12-31 | Skr32.77 Million ≈ $3.53 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.389x | +42.87% |
| 2019-12-31 | Skr25.11 Million ≈ $2.70 Million |
Skr-17.10 Million ≈ $-1.84 Million |
-0.681x | -132.57% |
| 2018-12-31 | Skr43.55 Million ≈ $4.69 Million |
Skr-12.75 Million ≈ $-1.37 Million |
-0.293x | +63.05% |
| 2017-12-31 | Skr7.38 Million ≈ $793.67K |
Skr-5.85 Million ≈ $-629.12K |
-0.793x | +28.05% |
| 2016-12-31 | Skr2.75 Million ≈ $296.05K |
Skr-3.03 Million ≈ $-326.18K |
-1.102x | -- |
About S2Medical AB
S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and… Read more